A new market analysis reveals that the Age-Related Molecular Degeneration (ARMD) Market is poised for significant growth, with its value projected to nearly double from USD 12.9 million in 2025 to USD 25.4 million by 2035. This robust expansion, representing a compound annual growth rate (CAGR) of 7.0%, is being fueled by an aging global population, increased awareness of ocular disorders, and continuous advancements in targeted therapies. The findings underscore a dynamic and evolving landscape where leading pharmaceutical companies are driving innovation to meet the growing demand for effective ARMD treatments.
Competitive Landscape: Dominance of Eylea and Key Players
The competitive landscape of the ARMD market in 2025 is dominated by a few key players and a leading product. Eylea, a therapy for age-related molecular degeneration, is projected to command a significant 42.5% share of the total market revenue. This commanding position is a testament to its proven clinical efficacy, a favorable safety profile, and its widespread adoption by physicians. The therapy’s ability to provide sustained visual acuity with fewer injections has contributed to high patient adherence and satisfaction. The market for ARMD treatments is a fiercely competitive arena, with top players including Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., and Amgen Inc., all of whom are actively engaged in research and development and strategic collaborations to strengthen their market presence.
Click Here for More Information:- https://www.futuremarketinsights.com/reports/age-related-macular-degeneration-market
Market Drivers: The Rising Tide of an Aging Population
A key driver of this market’s growth is the undeniable demographic shift toward an older global population. As the number of people aged 60 and over increases, so does the incidence of age-related eye disorders like macular degeneration. The World Health Organization estimates that by 2035, 12.1% of the world’s population will be 60 or older. This demographic trend creates a substantial and expanding patient base, particularly for Wet Age-Related Macular Degeneration (Wet AMD), which is expected to account for 65.0% of the market revenue in 2025. The high clinical burden and rapid progression of Wet AMD necessitate prompt and effective therapeutic interventions, making it a focal point for research and development.
Market Segmentation: Wet AMD and Hospital Pharmacies Lead the Way
The ARMD market is segmented by product, disease type, and distribution channel. Wet AMD is set to be the most prominent disease type segment, driving significant revenue due to the urgent need for treatment and advances in diagnostic technologies that facilitate early detection. From a distribution perspective, hospital pharmacies are projected to hold a leading 54.0% share of the market in 2025. This dominance is due to the complex storage and handling requirements of advanced biologics, which are best administered in a controlled clinical setting under the supervision of specialists. Strong coordination between ophthalmologists and hospital pharmacy services ensures a streamlined dispensing process and high standards of patient care.
Innovation and Research: Fueling Future Growth
The future of the ARMD market is bright, thanks to a continuous stream of innovation. The market is witnessing increased spending on research and development, with pharmaceutical companies and startups alike focusing on new therapeutic modalities and biosimilar adoption. These investments are yielding new drug approvals and treatments that promise improved efficacy and patient outcomes. For example, recent developments include Regeneron’s promising trial results for a higher-dose aflibercept and Samsung Bioepis’s approval of a biosimilar to Lucentis. Despite these advances, challenges such as a lack of awareness in some emerging economies and poor availability of certain products may restrain growth. However, a growing emphasis on personalized medicine, coupled with strategic collaborations and improved reimbursement frameworks, is expected to support sustained market expansion over the next decade.
Get Sample Report: – https://www.futuremarketinsights.com/reports/sample/rep-gb-16152
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
